TSL

Open App

Novo Nordisk After Wegovy: Can Five New Blockbusters Restart the Growth Story?

Educational research only — not investment advice.

Novo Nordisk stock is entering an important transition.

Wegovy and Ozempic turned Novo into one of the world’s largest pharmaceutical companies.

Now investors want to know:

What comes after semaglutide?

Novo says it aims to launch more than five major blockbuster medicines by 2030 and generate over 150 billion Danish kroner of pipeline sales by 2035.

Why Novo Needs New Growth

Wegovy still has enormous demand.

But Novo faces three major pressures:

  • stronger competition from Eli Lilly
  • lower drug prices
  • eventual semaglutide patent expirations

Eli Lilly’s Zepbound has gained market share quickly, while Novo investors are increasingly questioning whether obesity drugs alone can support long-term growth.

That means Novo needs a broader pipeline.

What Comes After Wegovy?

Novo is developing several next-generation medicines.

One of the most important is CagriSema, a combination obesity treatment designed to produce greater weight loss than existing therapies.

Another is zenagamtide, alongside several oral obesity treatments.

Novo also plans to have at least five Phase 3 programs in obesity and diabetes and another five in other therapeutic areas by 2030.

The company is therefore trying to move from:

one dominant franchise

to

multiple large growth products.

Weight-Loss Pills Could Be Huge

Novo’s CEO believes pills could eventually represent around 50% of the obesity-drug market by 2030.

That matters because pills are easier to distribute and may appeal to patients who dislike injections.

Novo already has oral Wegovy in the U.S. and is developing several additional pills.

If oral treatments expand the overall obesity market, Novo could reach millions of new patients.

But Competition Is Getting Harder

Novo is no longer competing only with Eli Lilly.

Roche, Pfizer, Amgen, AstraZeneca and several biotech companies are also developing weight-loss medicines.

More competition can mean:

lower prices + higher marketing costs + less market share

So even if the obesity market reaches $100 billion or more, Novo may capture a smaller percentage of it.

Why Investors Are Still Cautious

Novo shares fell sharply during its latest Capital Markets Day despite the company’s long-term targets.

Investors questioned pricing, M&A strategy and whether the pipeline can replace future semaglutide sales.

That highlights an important difference:

a promising pipeline is not the same as proven revenue.

Drug trials can fail.

Approvals can be delayed.

Competitors can launch better products.

What Should Investors Watch?

Watch Wegovy sales, CagriSema results, oral obesity drugs, Eli Lilly competition and new pipeline launches.

The central question is:

Can Novo turn today’s obesity leadership into several new blockbuster franchises before Wegovy’s growth slows?

If it succeeds, Novo could restart a broader growth story.

If not, investors may continue questioning how much of today’s valuation depends on one extraordinarily successful drug family.

Track Pharma Trends With TradingSimuLab

TradingSimuLab’s Trend Detector and Risk tools help users study changing sector momentum, market trends and risk conditions.

For more quantitative market research and educational trading tools, sign up to TradingSimuLab.

TradingSimuLab is for educational and research purposes only and does not provide investment advice.

MORE INSIGHTS

Continue exploring TradingSimuLab.

  • SOX Semiconductor Index Explained: What It Says About Nvidia, AMD and AI Stocks

    Nvidia can rise while the broader semiconductor market weakens. That is why investors watch the SOX Index. The PHLX Semiconductor Sector Index, commonly called the SOX, tracks 30 major U.S.-listed semiconductor companies involved in chip design, manufacturing, equipment and distribution. It provides a quick answer to an important question: Is the AI-chip trend broad—or being…

  • Margin Call Explained: How Leverage Can Turn a Market Selloff Into a Crash

    Leverage can magnify investment gains—but it can magnify losses even faster. When an investor borrows money to buy securities, falling prices can trigger a margin call. If the investor cannot provide more cash, the broker may sell positions. When this happens across many leveraged investors at once, forced selling can make a market decline much…

  • Oil Above $100: Why Crude Oil Futures Can Move Inflation, Stocks and the Fed

    Oil is back above $100 a barrel—and that matters far beyond energy markets. On September 15, Brent crude traded around $107.55, while U.S. West Texas Intermediate reached roughly $103.27 as attacks on Saudi energy infrastructure increased fears of tighter global supply. When crude oil rises this sharply, the effects can spread into inflation, interest rates,…

  • Silver Price Rally Explained: Why Silver Can Move Faster Than Gold

    Silver can behave like gold during a precious-metals rally—but its price often moves much faster in both directions. Silver climbed above $100 per ounce in January 2026, before suffering a dramatic correction. By September, it was trading around the mid-$60s. Why is silver so volatile? Because silver is simultaneously: a precious metalandan industrial commodity. That…

  • DRAM Stocks Explained: Why AI Is Creating a New Memory-Chip Boom

    AI is creating a new boom in memory chips—not just GPUs. As AI data centers expand, servers require huge amounts of DRAM to store and rapidly access data. That is tightening memory supply and increasing prices. For investors, companies such as Micron, Samsung and SK Hynix have therefore become important parts of the AI infrastructure…

  • AI Bubble Explained: Are AI Stocks Finally Facing an Expectations Reset?

    AI stocks have created enormous wealth—but investors are beginning to ask whether expectations have moved too far ahead of reality. On September 14, semiconductor stocks sold off sharply, with the PHLX chip index falling 5.9% as Nvidia, AMD, Broadcom and Micron came under pressure. At the same time, investors face a bigger question: Is AI…

  • Fed Rate Decision Explained: Why One Rate Hike Can Move Stocks, Bitcoin and Gold

    Few events move global markets as quickly as a Federal Reserve interest-rate decision. The Fed is widely expected to raise rates by 0.25 percentage points on September 16, 2026, taking its benchmark range to 3.75%–4.00%. But why can one small rate move affect stocks, Bitcoin, gold and bonds at the same time? Because the Fed…

  • 10-Year Treasury Yield Above 5%: Why High Bond Yields Can Hit Stocks Hard

    The U.S. 10-year Treasury yield has crossed 5%, creating a major new test for stocks. On September 15, 2026, the benchmark yield rose above 5.02%, its highest level since 2007. Rising oil prices, inflation concerns and heavy bond supply have all contributed to the move. Why should stock investors care? Because a 5% Treasury yield…

  • MAS Monetary Policy Explained: Why Singapore Uses the Exchange Rate Instead of Interest Rates

    Singapore runs monetary policy differently from most major economies. The U.S. Federal Reserve changes interest rates. The European Central Bank changes interest rates. But the Monetary Authority of Singapore (MAS) mainly manages the Singapore dollar’s exchange rate. Why? Because Singapore is a small, highly open economy where imports and exports are enormous relative to GDP.…

TRADINGSIMULAB

Continue your market research with TradingSimuLab.

Explore TradingSimuLab’s five-model research framework, watchlist and tools for trend, timing, macro and risk analysis.

Open app